New Zealand - English - Medsafe (Medicines Safety Authority)

regional health ltd - barium sulfate 96.426%{relative};  ;   - powder for enema - 6.426% w/w - active: barium sulfate 96.426%{relative}     excipient: carrageenan pectin polyoxyethylene glyceryl mono-oleate simeticone sodium citrate dihydrate sorbitol tragacanth

Ireland - English - HPRA (Health Products Regulatory Authority)

bracco imaging spa - barium sulfate - powder for rectal suspension - 96.5 percent weight/weight - barium sulfate containing x-ray contrast media; barium sulfate with suspending agents

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 20 mg in 1 ml - readi-cat 2 and readi-cat 2 smoothies are indicated for use in computed tomography (ct) of the abdomen to delineate the gastrointestinal (gi) tract in adult and pediatric patients. readi-cat 2 products are contraindicated in patients: - with known or suspected perforation of the gi tract - with known obstruction of the gi tract - at high risk of gi perforation such as those with a recent prior gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to pelvis - at high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of readi-cat 2 or readi-cat 2 smoothies risk summary readi-cat 2 products are not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary readi-cat 2 products are not absorbed systemically by

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 0.6 g in 1 ml - liquid e-z-paque is indicated for use in single contrast radiographic examinations of the esophagus, stomach, and small bowel to visualize the gastrointestinal (gi) tract in adult and pediatric patients. liquid e-z-paque is contraindicated in patients with the following conditions: - known or suspected perforation of the gi tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of liquid e-z-paque risk summary liquid e-z-paque is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . risk summary liquid e-z-pa

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 960 mg in 1 g - e-z-paque is indicated for use in single contrast radiographic examinations of the esophagus, stomach, duodenum and small bowel to visualize the gastrointestinal tract (gi) in adult and pediatric patients. e-z-paque is contraindicated in patients with the following conditions: - known or suspected perforation of the gi tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent prior gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation - with known severe hypersensitivity to barium sulfate or any of the excipients of e-z-paque risk summary e-z-paque is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . risk summary e-z-paque is not absorb

New Zealand - English - Medsafe (Medicines Safety Authority)

regional health ltd - barium sulfate 96.87%{relative} - powder for oral suspension - 96.87% w/w - active: barium sulfate 96.87%{relative} excipient: carmellose sodium citric acid monohydrate tabbletting compoumd no 3 bubble breaker. methyl hydroxybenzoate nonoxinol 9 propyl hydroxybenzoate purified water saccharin sodium simeticone sodium citrate dihydrate sorbitol

New Zealand - English - Medsafe (Medicines Safety Authority)

hanimex (nz) ltd - barium sulfate 96.6375%{relative} - powder for oral suspension - 96.63% w/w - active: barium sulfate 96.6375%{relative}

United States - English - NLM (National Library of Medicine)

genus medical technologies, llc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 96 g in 100 g - for use as a contrast agent in radiographic studies. this product should not be used in patients with known or suspected gastric or intestinal perforation, patients with conditions that may increase the risk of perforation; hypersensitivity to barium sulfate products; suspected tracheoesophageal fistula; obstructing lesions of the small intestine; pyloric stenosis; inflammation or neoplastic lesions of the rectum; or in patients who have had a recent rectal biopsy. barium sulfate suspensions should not be used for infants with swallowing disorders or for newborns with complete duodenal or jejunal obstruction or when distal small bowel or colon obstruction is suspected. barium sulfate suspension is not recommended for very small preterm infants and young babies requiring small volumes of contrast media or for infants and young children when there is a possibility of leakage from the gastrointestinal tract, such as nectrotizing enterocolitis, unexplained pneumoperitoneum, gasless abdomen, other bowel perforatio

Israel - English - Ministry of Health

promedico ltd - barium sulfate - powder for suspension - barium sulfate 96.476 %w/w - barium sulfate without suspending agents - barium sulfate without suspending agents - for rectal administration (enema) as a radio-opaque agent for x-ray visualisation of the lower gastro-intestinal tract. it is designed for both single contrast barium enema and air-double contrast enema usage.

New Zealand - English - Medsafe (Medicines Safety Authority)

regional health ltd - barium sulfate 96%{relative} - powder for oral suspension - 96% w/w - active: barium sulfate 96%{relative} excipient: bentonite carmellose sodium maltodextrin orange flavour saccharin sodium sodium benzoate sodium polymetaphosphate